Healthcare Industry News: Cadence Pharmaceuticals
News Release - August 14, 2006
Cadence Pharmaceuticals Appoints James B. Breitmeyer, M.D., Ph.D. as Chief Medical Officer and Names Christopher J. Twomey to Its Board of DirectorsSAN DIEGO, Aug. 14 (HSMN NewsFeed) -- Cadence Pharmaceuticals, Inc. announced today that it has appointed James B. Breitmeyer, M.D., Ph.D. to the position of Executive Vice President, Development and Chief Medical Officer. The company also announced the appointment of Christopher J. Twomey to its Board of Directors.
Mr. Twomey is currently the Senior Vice President, Finance and Chief Financial Officer of Biosite Incorporated, a publicly traded medical diagnostic company. During his tenure at Biosite he played an integral role in its transition from a privately held company to a publicly traded company. Prior to his tenure at Biosite, which began in March 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey currently serves on the board of directors of Senomyx, Inc., a biotechnology company, where he serves as Chair of the Audit Committee. He received his B.A. in business economics from the University of California at Santa Barbara.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Cadence currently has two Phase 3 products in development, including one for the treatment of acute pain and one for the prevention of catheter-related infections.
Source: Cadence Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.